Literature DB >> 28198999

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.

Shirley D'Sa1, Marie José Kersten2, Jorge J Castillo3, Meletios Dimopoulos4, Efstathios Kastritis4, Edward Laane5, Véronique Leblond6, Giampaolo Merlini7, Steven P Treon3, Josephine M Vos2,8, Michael P Lunn9.   

Abstract

Paraproteinaemic neuropathies are a heterogeneous group of disorders most frequently associated with IgM monoclonal gammopathies including Waldenström macroglobulinaemia (WM). Their consequences are significant for affected patients, and their management challenging for their physicians. The variability in clinical presentation and time course hamper classification and management. The indications for invasive investigations such as cerebrospinal fluid analysis, nerve conduction tests and sensory nerve biopsies are unclear, and the optimum way to measure clinical response to treatment unknown. When to intervene and and how to treat, also present challenges to physicians. As part of its latest deliberations at the International Workshops on WM (IWWM) in London, UK (August 2014), the IWWM8 panel have proposed a consensus approach to the diagnosis and management of peripheral neuropathies associated with IgM monoclonal gammopathies, including WM. Importantly, a consensus regarding the use of clinical outcome measures and recommended models of care for this group of patients is discussed, as well as appropriate treatment interventions.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  IgM; Waldenstrom macroglobulinaemia; paraproteinaemic neuropathy

Mesh:

Substances:

Year:  2017        PMID: 28198999     DOI: 10.1111/bjh.14492

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies.

Authors:  Jean-Sebastien Allain; Florian Thonier; Morgane Pihan; Marie-Laure Boulland; Sophie de Guibert; Vincent Launay; Anne-Violaine Doncker; Michel Ganard; Amyra Aliouat; Céline Pangault; Roch Houot; Marie De Tayrac; Thierry Lamy; Mikael Roussel; Thierry Fest; Olivier Decaux; Cedric Pastoret
Journal:  Haematologica       Date:  2018-01-25       Impact factor: 9.941

2.  [18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström's Macroglobulinemia.

Authors:  Thomas A Fox; Michael Lunn; Ashutosh Wechalekar; Jamshed Bomanji; Simon Wan; Shirley D'Sa
Journal:  Haematologica       Date:  2018-04-12       Impact factor: 9.941

Review 3.  Toward personalized treatment in Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.

Authors:  Louis-Pierre Girard; Cinnie Yentia Soekojo; Melissa Ooi; Wee Joo Chng; Sanjay de Mel
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

5.  CANOMAD unmasked by COVID-19 in a man with Waldenström's macroglobulinaemia.

Authors:  Hamish D Morrison; Jonathan Cleaver; Natasha Lander; Philippa Lowden; Kate Hale; Kanchan Sharma; James Stevens
Journal:  EJHaem       Date:  2021-08-12

Review 6.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

Review 7.  An update on the diagnosis and management of the polyneuropathy of POEMS syndrome.

Authors:  Federica Cerri; Yuri Matteo Falzone; Nilo Riva; Angelo Quattrini
Journal:  J Neurol       Date:  2018-09-27       Impact factor: 4.849

8.  Waldenström's macroglobulinemia front line treatment.

Authors:  Alessandra Tedeschi; Anna Maria Frustaci
Journal:  Hemasphere       Date:  2019-06-30

Review 9.  Advances in the understanding of IgM monoclonal gammopathy of undetermined significance.

Authors:  Jonas Paludo; Stephen M Ansell
Journal:  F1000Res       Date:  2017-12-18

Review 10.  Waldenström macroglobulinemia treatment algorithm 2018.

Authors:  Morie A Gertz
Journal:  Blood Cancer J       Date:  2018-05-01       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.